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doi:10.1016/j.hkjn.2012.01.004Summary Background/Purpose: Human oxoguanine-DNA glycosylase 1 (hOGG1) is the
enzyme that has DNA repairing capacity. C1245 G substitution of the hOGG1 gene results in
reduced enzyme activity. Peritoneal dialysis (PD) is known to cause oxidative DNA damage.
We investigated the effect of hOGG1 polymorphism on the clinical outcomes of PD patients.
Methods: We studied the hOGG1 polymorphism in 441 new PD patients (232 men, age
56.6  13.5 years). The patients were followed for 41.4  18.2 months for cardiovascular
events.
Results: For the entire cohort, there was no significant difference in the 5-year event-free
survival between the CC and CG/GG groups (42.9% vs. 33.2%; pZ 0.1). However, for patients
with baseline serum C-reactive protein (CRP) levels  5.0 mg/L, 5-year event-free survival of
the CC group was significantly better than that of CG/GG group (50.3% vs. 31.9%, pZ 0.046).
Multivariate analysis showed that hOGG1 polymorphism was an independent predictor of the
survival (pZ 0.008). In contrast, for patients with baseline CRP > 5.0 mg/L, there was no
significant difference in 5-year event-free survival between the CC and CG/GG groups
(26.7% vs. 30.2%, pZ 0.9).
Conclusion: In PD patients with no systemic inflammation, hOGG1 1245CC genotype confers
a survival benefit as compared to CG or GG genotype, but the protective effect disappears
in patients with systemic inflammation. Our results suggest a complex interaction between
hOGG1 and inflammation in the pathogenesis of cardiovascular disease in PD patients.
背景: 人類oxoguanine-DNA glycosylase 1 (hOGG1)是一種具DNA修復能力的酵素，其酵素活動在
hOGG1基因的C1245G替換後會有所下降。此外，腹膜透析(PD)已知會導致DNA的氧化性損害。本
研究調查了hOGG1多態性對PD患者的影響。of Medicine & Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, N.T.,
.hk (C.-C. Szeto).
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hOGG1 polymorphism in PD 25方法: 研究人員對441位剛開始接受PD的病人(男232人, 年齡56.6  13.5歲)，作出hOGG1多態性
的調查，並對心血管事件的發生進行共41.4  18.2個月的追蹤。
結果: 在整體病人中，CC與CG/GG組別之間在5年無事件存活率上無明顯差異(42.9% vs. 33.2%,
p Z 0.1)；然而，在基線血清C-反應蛋白(CRP)水平  5.0 mg/L的病人中，CC組的5年無事件存
活率明顯高於CG/GG組(50.3% vs. 31.9%, p Z 0.046)。多變數分析顯示，hOGG1多態性是存活
的獨立預測因子(p Z 0.008)。相反，在基線CRP > 5.0 mg/L的病人中， CC與CG/GG組別之間
在5年無事件存活率上並無明顯差異(26.7% vs. 30.2%, p Z 0.9)。
結論: 在不具系統性發炎的PD患者間，相比於CG或GG基因型，hOGG1 1245CC基因型具備若干的
存活效益，但其效益並未出現於系統性發炎患者間。這些結果意味著，在PD患者的心血管致病過
程中，hOGG1與發炎之間存在著複雜的交互關係。Introduction
Peritoneal dialysis (PD) is the first line renal replacement
therapy in Hong Kong.1,2 Most PD patients can enjoy an
impressive survival rate, low peritonitis rate, and an
excellent quality of life during the treatment.2 However,
PD is known to cause oxidative stress, which may aggravate
atherosclerotic lesions.3e5 In fact, cardiovascular disease is
the major cause of morbidity and mortality in PD patients.6
In hemodialysis (HD) patients, the interaction of
phagocytes with complement-activating membranes during
the HD process results in oxidative stress.7,8 The conse-
quence of this is the secretion of various reactive oxygen
species (ROS), which can react with and destruct various
macromolecules, including DNA. By using leukocyte 8-
hydroxy-2’-deoxyguanosine (8-OHdG), a product of DNA
oxidative damage, as a marker, it was found that HD
patients had significantly higher levels of 8-OHdG when
compared with renal failure patients without HD and
healthy controls.7 In hypertensive patients with different
stages of chronic kidney disease (CKD), 8-OHdG was posi-
tively associated with more severe proteinuria.9 8-OHdG
was also found to positively correlate with severity of
coronary artery disease (CAD).10
Human oxoguanine-DNA glycosylase 1 (hOGG1) is the
enzyme catalyzes the removal of 8-OHdG from damaged
DNA.11e13 hOGG1 is encoded by hOGG1 gene, which is
located on chromosome 3p26.2. A C/G substitution at
position 1245 in exon 7 of the gene is associated with a serine
(ser) to cysteine (cys) substitution at codon 326.14 Cys326
enzyme was found to have lower DNA repairing capacity
when compared with Ser326 enzyme.14e17 HD patients with
the GG genotype of the hOGG1 gene were found to have
significantly higher leukocyte 8-OHdG content when
compared with patients with CG or CC genotype.18,19
As in HD, patients undergoing PD also subject to oxida-
tive stress and the resulting oxidative DNA damage.20,21
Exposure to dialysis solutions, glucose degradation prod-
ucts (GDPs), and advanced glycation end products (AGEs)
are all oxidative challenge to peritoneal and immune
cells. However, the effects of hOGG1 C1245 G poly-
morphism in PD patients have not been reported. In the
present study, we investigate the effect of the poly-
morphism on the clinical outcomes of Chinese PD patients
in whom cardiovascular problems cause major morbidity
and mortality.6Methods
Study population
We studied 441 patients newly put on PD in our unit. Those
who were unlikely to survive for 6 months, who planned to
have elective living donor transplant, or who would be
transferred to other renal centers within 6 months were
excluded. The presence of diabetes, hypertension, and
a history of cardiovascular disease were recorded. Hyper-
tension was defined according to the Join National
Committee VII criteria.22 The definition of cardiovascular
disease has been described previously.23 Serum C-reactive
protein (CRP) was measured at the initiation of dialysis by
our in-house high sensitivity assay. This study was approved
by the Clinical Research Ethical Committee of the Chinese
University of Hong Kong. Informed consent was obtained
from all the patients.
hOGG1 C1245G genotyping
Genomic DNA of the patients was extracted from blood by
standard method. Genotyping was done by using poly-
merase chain reaction and restriction fragment length
polymorphism (PCR-RFLP) as described by Tarng and
colleagues18 with some modifications. All the reagents used
in polymerase chain reaction (PCR) were obtained from
Roche Diagnostics (Mannheim, Germany). The restriction
enzyme Fnu4HI was obtained from New England Biolabs Inc.
(Ipswich, MA, USA). The primers used are 5’ AGG GGA AGG
TGC TTG GGG AA 3’ (forward) and 5’ ACT GTC ACT AGT CTC
ACC AG 3’ (reverse). In a 20-ml PCR mixture, 50 ng genomic
DNA was mixed with 1 PCR buffer, 0.2 pmol/ml forward
and backward primers, 2.0 mM magnesium chloride, 0.2 mM
nucleotides, and 0.4 U Taq polymerase. The thermal cycling
condition included an initial denaturing at 94 C for 2
minutes, followed by 30 cycles of denaturing at 94 C for 15
seconds, annealing at 58 C for 15 seconds and extension at
72 C for 40 seconds. The final extension was 72 C for 5
minutes. The PCR product (200 bp) was digested with 2.5 U
Fnu4HI and separated in 2% agarose gel stained with
ethidium bromide. A homozygous CC sample had an uncut
200-bp band. The PCR product from the homozygous GG
sample had a recognition site of Fnu4HI, which cut the 200-
bp product into two 100-bp bands. The heterozygous CG
sample had 100-bp and 200-bp bands.
Table 1 Baseline clinical and demographic data.
Genotype group CC CG/GG
Number of patients 73 368
Sex (M:W) 37:36 195:173
Age (y) 58.0 13.8 56.4 13.4
Body height (cm) 159.0 9.0 159.6 11.8
Body weight (kg) 60.3 11.0 60.2 11.7
Body mass index (kg/m2) 23.9 4.3 23.5 4.2
Renal diagnosis, n (%)
Glomerulonephritis 20 (27.4%) 104 (28.3%)
Diabetic nephropathy 30 (41.1%) 128 (34.8%)
Polycystic kidney 1 (1.4%) 13 (3.5%)
Hypertensive nephrosclerosis 4 (5.5%) 31 (8.4%)
Obstructive uropathy 5 (6.8%) 19 (5.2%)
Others/unknown 13 (17.8%) 73 (19.8%)
Comorbid conditions, n (%)
Coronary heart disease 18 (24.7%) 81 (22.0%)
Congestive heart failure 18 (24.7%) 67 (18.2%)
Cerebrovascular disease 15 (20.5%) 80 (21.7%)
Peripheral vascular disease 7 (9.6%) 26 (7.1%)
Charlson’s comorbidity index 5.4 2.4 5.3 2.3
Table 2 Baseline peritoneal transport, dialysis adequacy,
and nutritional status.
Genotype group CC CG/GG
Patients, n 73 368
Peritoneal transport
D/P creatinine at 4 hours 0.66 0.14 0.63 0.14
MTAC creatinine
(mL/minute/1.73 m2)
10.57 5.58 9.71 5.20
Dialysis adequacy and nutritional status
Weekly total Kt/V 2.21 0.87 2.20 0.52
Residual GFR
(mL/minute/1.73 m2)
3.47 2.35 3.56 2.27
Serum albumin (g/L) 31.3 4.6 31.5 5.6
NPNA (g/kg/day) 1.11 0.29 1.12 0.25
FEBM (%) 42.4 10.5 43.1 11.2
D/PZ dialysate-to-plasma ratio; FEBMZ fat-free edema-free
body mass; GFRZ glomerular filtration rate; MTACZmass
transfer area coefficient; NPNAZ normalized protein nitrogen
appearance.
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All patients were followed from 2002 to 2008. The clinical
management and dialysis regimen were decided by an
individual nephrologist and were not affected by the study.
The primary end point was a composite one that consists of
cardiovascular death, nonfatal myocardial infarction or
stroke, hospital admission for pulmonary edema, unstable
angina, coronary intervention, transient ischemic attack, or
lower limb ischemia. Secondary end points included dura-
tion of hospitalization for all-cause, all-cause mortality,
cardiovascular mortality, and technique survival. Censoring
events for survival analysis included transfer to long-term
hemodialysis, kidney transplant, recovery of renal func-
tion, loss to follow-up, and transfer to other dialysis
centers.
Statistical analysis
Statistical analysis was performed by SPSS for Windows
software version 15.0 (SPSS Inc., Chicago, IL, USA). Data
were expressed as mean standard deviation. Comparisons
between groups were performed by Chi-square test,
Student’s t-test, or one-way analysis of variance (ANOVA) as
appropriate. Kaplan-Meier analysis and the log rank test
were used to explore the effect of genotype on the clinical
end points. In addition to the hOGG1 C1245 G poly-
morphism, we also added baseline glomerular filtration rate
(GFR), total Kt/V, serum albumin (Alb), subjective global
assessment (SGA), Charlson’s comorbidity score, age, and
diabetic status into the Cox proportional hazard model to
look for independent predictors of clinical outcome. A
backward stepwise analysis was applied to remove insig-
nificant variables. A p value below 0.05 was considered
statistically significant. All probabilities were two-tailed.
Results
We recruited 441 patients; 73 (16.6%) had CC, 194 (44.0%)
had CG, and 174 (39.4%) had GG genotype. The genotype
distribution is in agreement with Hardy-Weinberg equilib-
rium (chi-square test, pZ 0.6). The demographic and
baseline clinical information of the patients are summa-
rized and compared in Table 1. Peritoneal transport, dial-
ysis adequacy, and nutritional status are compared in
Table 2. In essence, the CC and CG/GG groups were highly
comparable in all baseline clinical and laboratory
parameters.
Primary end point
The average follow-up was 41.4 18.2 months. A total of
269 (61.0%) patients developed the primary composite end
point. The events contributing to the primary composite
end point were admission for pulmonary edema (186 cases),
acute coronary syndrome or elective coronary intervention
(64 cases), and cerebrovascular accident (19 cases). The 5-
year event-free survival of the CC group was marginally
higher than that of the CG/GG group (42.9% vs. 33.2%, log-
rank test pZ 0.1), although the difference did not reach
statistical significance.Even though the 5-year survival between the CC and
CG/GG groups were not significantly different in the whole
cohort, we found that there was a trend of interaction
between CRP levels and the hOGG1 C1245 G polymorphism
on the primary outcome (pZ 0.081). A posthoc analysis
showed that for patients with CRP levels  5.0 mg/L, 5-year
event-free survival of CC group was significantly better than
that of CG/GG group (50.3% vs. 31.9%, pZ 0.046). These
results are shown in Fig. 1. In this group of patients,
multivariate Cox regression analysis showed that both the
hOGG1 polymorphism and Charlson’s comorbidity index
were independent predictors of the 5-year event-free
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Figure 2 Kaplan Meier plot of event-free survival for peri-
toneal dialysis patients with baseline C-reactive protein >
5 mg/L.
follow up (months)
0 12 24 36 48 60
Ev
en
t-f
re
e 
su
rv
iva
l (%
)
0
20
40
60
80
100
hOGG1 1245CC
hOGG1 1245CG/GG
log rank test, p = 0.046
Figure 1 Kaplan Meier plot of event-free survival for peri-
toneal dialysis patients with baseline C-reactive protein 
5 mg/L.
hOGG1 polymorphism in PD 27survival (Table 3). By contrast, there was no significant
difference in 5-year event-free survival between the CC
and CG/GG groups for patients with CRP > 5.0 mg/L (26.7%
vs. 30.2%, pZ 0.9). These results are shown in Fig. 2.
Secondary end points
During the follow-up period, 212 (48.1%) patients died. The
causes of death were cardiovascular diseases (75 cases),
cerebrovascular accident (23 cases), peritonitis (32 cases),
nonperitonitis infections (40 cases), termination of dialysis
(19 cases), malignancy (5 cases), liver failure (3 cases), and
other specific causes (15 cases). During the study period, 58
patients had kidney transplantation, 35 changed to hemo-
dialysis, 15 were transferred to other centers, and one
patient had recovered renal function. The CC and CG/GG
groups had similar 5-year actuarial survival (54.0% vs.
59.1%, pZ 0.5), technique survival (42.6% vs. 45.0%,
pZ 0.9), and cardiovascular survival (83.0% vs. 77.1%,
pZ 0.7). There was no significant interaction between CRP
levels and the hOGG1 C1245 G polymorphism on 5-year
actuarial survival or cardiovascular survival of the
patients (details not shown).Table 3 Multivariate analysis by Cox model for 5-year
event-free survival of peritoneal dialysis patients with
C-reactive protein  5 mg/L.
AHR 95% CI p value
hOGG1 C1245
G polymorphism
3.989 1.445 e 11.013 0.008
Charlson’s
comorbidity index
1.266 1.127 e 1.422 <0.001
AHRZ adjusted hazard ratio; CIZ confidence interval.During the study period, there were 1537 hospital
admissions for a total of 8680 days. The CC and CG/GG
groups had similar number of hospital admission (3.4 2.4
vs. 3.5 3.2 episodes/year, pZ 0.7) and duration of hospi-
talization (19.0 16.2 vs. 19.8 19.1 days/year, pZ 0.7).
Discussion
By using 8-OHdG as marker, it was proved that both HD and
PD processes could cause oxidative stress and the resulting
oxidative DNA damage.20,21 Oxidative stress is one of the
causative mechanisms of cardiovascular problems. In
patients with cardiovascular diseases, it was found that 8-
OHdG contents in the blood, myocardium, and white cells
were significantly higher than that in normal controls.24,25
Human oxoguanine-DNA glycosylase 1 catalyzes the exci-
sion of 8-OHdG from oxidatively damaged DNA and prevents
the mutagenic GC to TA transversions.11e13 A C/G substi-
tution at position 1245 in exon 7 of the hOGG1 gene is
associated with a serine (ser) to cysteine (cys) substitution
at codon 326.14,26 The substitution resulted in an enzyme
(cys326) having lower DNA repairing capacity when
compared with wild-type enzyme (ser326).14e17 In HD
patients, GG genotype had significantly higher leukocyte
8-OHdG content when compared with CG or CC geno-
type.18,19 In a recent study of patients with CAD, CG and
GG genotypes was found to associate with higher
risk of multivessel disease when compared with the CC
genotype.
Our present study is the first to investigate the effect of
hOGG1 C1245 G polymorphism on clinical outcome of PD
patients. The genotype distribution of our patients is not
significantly different from that of the normal Taiwanese
and Taiwanese undergoing HD.18,19 We showed that 5-year
event-free survival of the CC group was not significantly
28 P.Y.-K. Poon et al.different from that of the CG/GG group in the whole
cohort. However, we found that there was substantial
interaction between CRP levels and the polymorphism on 5-
year event-free survival. For patients with baseline CRP
levels  5.0 mg/L, 5-year event-free survival of CC group
was significantly better than that of the CG/GG group. We
used a CRP level of 5 mg/L as the cut off for subgroup
analysis because this is the upper limit of normal of our
assay (defined as mean level plus two standard deviations in
healthy volunteers). Our result indicates that the effect of
the polymorphism on survival can be affected by the
inflammatory status of the patients. But, the mechanism
of interaction is not completely known. One possible
explanation is the inflammation-induced nitric oxide (NO)
secretion. During inflammatory process, inflammatory
mediators cause the increase transcription of inducible
nitric oxide synthase (iNOS) in macrophages, which results
in the increase production of NO.27,28 Actually, spent dial-
ysate was found to contain various inflammatory cytokines
with stimulatory effects on peritoneal cells.29 Davenport
and colleagues30 demonstrated that spent dialysate had
significant amount of NO when compared with the unused
dialysis solution. In vitro experiment showed that both
peritoneal macrophages and peritoneal mesothelial cells
from PD patients produced NO when they were cultured in
spent dialysate.30 In our present study, patients with
inflammation might have generated enough NO to inhibit
the activity of hOGG1 irrespective to the genotypes of the
patients were. This could explain the lack of effect of the
polymorphism on survival of the patients when the CRP
levels of the patients were above 5 mg/L.
Another possible explanation of the results of our present
study is oxidative stress. It is now known that inflammation
and oxidative stress are the two major problems encoun-
tered by patients with end-stage renal disease (ESRD).
However the causal relationship between the two reactions
is still not very conclusive.31e34 Evidence indicates that
increased inflammation is associated with increased oxida-
tive stress.35,36 Thus, it is logical to deduce a larger degree of
oxidative stress in our PD patients who had more severe
inflammation. In vitro study showed that oxidative stress
could decrease hOGG1 protein expression.37 The suppressive
effect of oxidative stress on hOGG1 was probably not
affected by the genotypes of the hOGG1 polymorphism. This
could explain the lack of effect of genotype on event-free
survival of PD patients who had inflammation.
There are a number of inadequacies of our present
study. Firstly, we only had the baseline CRP data of the
patients. The inflammatory status and the extent of
oxidative stress of our patients, such as inflammatory and
oxidative markers in blood and dialysates, had not been
quantified during the process of PD, and these data might
be relevant in correlating inflammation and oxidative stress
with the effect of hOGG1 C1245 G polymorphism on survival
of the patients. Secondly, we did not explore the physio-
logic significance of the polymorphism, which we believe
has been adequately tested in previous studies by other
groups.18,19 Thirdly, we did not quantify the severity of
vascular atherosclerosis (for example, by pulse wave
velocity or ankle-brachial indices) or peritoneal transport
characteristics for our patients, although both of which
theoretically may be affected by the polymorphism.In conclusion, hOGG1 1245CC genotype conferred
a cardiovascular event-free survival advantage to PD
patients without systemic inflammation. The protective
effect of the CC genotype, however, disappeared in
patients with feature of systemic inflammation. Our results
suggest a complex interaction of the enzyme hOGG1, the
systemic inflammatory status, and probably the oxidative
status of the PD patients in the pathogenesis of cardiovas-
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